Analyst Ratings For Inovio Pharmaceuticals Inc (NASDAQ:INO)
Today, HC Wainwright initiated coverage on Inovio Pharmaceuticals Inc (NASDAQ:INO) with a Buy with a price target of $13.00.
There are 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Inovio Pharmaceuticals Inc (NASDAQ:INO) is Buy with a consensus target price of $10.75 per share, a potential 105.94% upside.
Some recent analyst ratings include
- 12/5/2018-Inovio Pharmaceuticals Inc (NASDAQ:INO) has coverage initiated with a Buy rating and $13.00 price target
- 10/2/2018-Inovio Pharmaceuticals Inc (NASDAQ:INO) has coverage initiated with a Buy ➝ Buy rating and $8.00 price target
- 10/6/2017-Inovio Pharmaceuticals Inc (NASDAQ:INO) has coverage initiated with a Buy rating and $10.00 price target
- 7/18/2017-Inovio Pharmaceuticals Inc (NASDAQ:INO) had its Buy rating reiterated by Aegis with a $14.00 price target
- 6/8/2017-Inovio Pharmaceuticals Inc (NASDAQ:INO) gets upgraded to Overweight by Piper Jaffray Companies with a price target of $14.00
- On 11/29/2018 Peter Kies, CFO, sold 10,001 with an average share price of $5.28 per share and the total transaction amounting to $52,805.28.
- On 9/12/2018 Jong Joseph Kim, CEO, sold 49,060 with an average share price of $5.37 per share and the total transaction amounting to $263,452.20.
- On 7/10/2018 Peter Kies, CFO, sold 35,000 with an average share price of $4.44 per share and the total transaction amounting to $155,400.00.
- On 4/16/2018 David B Weiner, Director, sold 9,000 with an average share price of $4.91 per share and the total transaction amounting to $44,190.00.
- On 4/12/2018 Jong Joseph Kim, CEO, sold 103,750 with an average share price of $5.14 per share and the total transaction amounting to $533,275.00.
- On 4/12/2018 Simon X Benito, Director, sold 3,750 with an average share price of $5.23 per share and the total transaction amounting to $19,612.50.
- On 5/25/2017 David B Weiner, Director, sold 8,000 with an average share price of $8.00 per share and the total transaction amounting to $64,000.00.
About Inovio Pharmaceuticals Inc (NASDAQ:INO)
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers; prostate, breast, lung, and pancreatic cancers; hepatitis C virus; hepatitis B virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, LLC, The Wistar Institute, University of Pennsylvania, GeneOne Life Science Inc., Regeneron Pharmaceuticals, Inc., Genentech, Inc., Plumbline Life Sciences, Inc., the Parker Institute for Cancer Immunotherapy, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, National Institute of Allergy and Infectious Diseases, United States Military HIV Research Program, U.S. Army Medical Research Institute of Infectious Diseases, National Institutes of Health, HIV Vaccines Trial Network, Defense Advanced Research Projects Agency, and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Recent Trading Activity for Inovio Pharmaceuticals Inc (NASDAQ:INO)
Shares of Inovio Pharmaceuticals Inc closed the previous trading session at 5.22 −0.19 3.51% with 5.2 shares trading hands.